12.69% -0.97

Altimmune Inc (ALT)

Altimmune Inc Borsa (ALT) Ultime notizie

Altimmune Inc (ALT)

Altimmune Inc Borsa (ALT) Ultime notizie

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune ... - GlobeNewswire

Holzer & Holzer, LLC Reminds Shareholders of July 5, 2024 Lead Plaintiff Deadline in Altimmune, Inc. (ALT) Class ... - GlobeNewswire

Altimmune Appoints Andrew Shutterly as New CFO - TipRanks.com - TipRanks

Altimmune Chief Financial Officer Richard Eisenstadt Dies - MarketWatch

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt

Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT) - PR Newswire

Altimmune (NASDAQ:ALT) Given “Buy” Rating at B. Riley - Defense World

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Short ALT: Altimmune Inc. faces bearish rejection at major resistance, targeting recent lows - Invezz

Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action ... - Marketscreener.com

Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action ... - PR Newswire

ADA 2024: Altimmune's GLP-1 drug shows weight loss potential - Clinical Trials Arena

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial ... - GlobeNewswire

ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline - ForexTV.com

Altimmune, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm - The Bakersfield Californian

Altimmune, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm - ForexTV.com

Altimmune reports positive results in weight-loss drug trial - Yahoo Finance

ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of ... - GlobeNewswire

ADA 2024: Altimmune’s GLP-1 drug shows weight loss potential - Pharmaceutical Technology

Altimmune Inc (ALT) Stock: Navigating a Year of Stock Volatility - The InvestChronicle

ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings - InvestorPlace

ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings - InvestorPlace

Altimmune (NASDAQ:ALT) Shares Gap Up to $6.41 - Defense World

How did Altimmune Inc (ALT) fare last session? – US Post News - US Post News

Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass - BioSpace

Altimmune jumps 13% on phase 2 pemvidutide results for obesity - Seeking Alpha

Altimmune Stock Is Rising Monday: What's Driving The Action? - Altimmune (NASDAQ:ALT) - Benzinga

Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data - Yahoo Finance

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Alnylam ... - Benzinga

Altimmune Shares Rise on Positive Data From Obesity-Drug Trial - MarketWatch

IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class ... - AccessWire

Altimmune stock price is still at risk despite Pemvidutide hopes - Invezz

Brokerages Set Altimmune, Inc. (NASDAQ:ALT) PT at $18.80 - Defense World

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions - ForexTV.com

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the ... - Yahoo Finance

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important ... - GlobeNewswire

ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline - EIN News

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Markets Insider

UPCOMING ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class ... - AccessWire

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions - ForexTV.com

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at ... - StockTitan

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm - ForexTV.com

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified ... - GlobeNewswire

Analysts Set Altimmune, Inc. (NASDAQ:ALT) PT at $18.80 - MarketBeat

Piper Sandler Reaffirms Overweight Rating for Altimmune (NASDAQ:ALT) - MarketBeat

Forecasting The Future: 5 Analyst Projections For Altimmune - Altimmune (NASDAQ:ALT) - Benzinga

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Morningstar

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune ... - GlobeNewswire

Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune ... - GlobeNewswire

Simile a ALT